These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9917123)

  • 1. When should patients with heterozygous familial hypercholesterolemia be treated?
    Rifkind BM; Schucker B; Gordon DJ
    JAMA; 1999 Jan; 281(2):180-1. PubMed ID: 9917123
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel pharmacological treatments for children and adolescents with heterozygous familial hypercholesterolemia.
    Wiegman A; Hutten BA
    Expert Rev Clin Pharmacol; 2017 Sep; 10(9):919-921. PubMed ID: 28756723
    [No Abstract]   [Full Text] [Related]  

  • 3. Familial hypercholesterolemia: current treatment and advances in management.
    Huijgen R; Vissers MN; Defesche JC; Lansberg PJ; Kastelein JJ; Hutten BA
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):567-81. PubMed ID: 18402545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Should children with familial hypercholesterolemia be treated with statins?].
    Tonstad S
    Lakartidningen; 2004 Oct; 101(44):3406. PubMed ID: 15560654
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined drug therapy--cholestyramine and compactin--for familial hypercholesterolemia.
    Yamamoto A; Yamamura T; Yokoyama S; Sudo H; Matsuzawa Y
    Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):493-7. PubMed ID: 6500769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities.
    Vuorio A; Watts GF; Kovanen PT
    J Clin Lipidol; 2016; 10(5):1278-9. PubMed ID: 27678448
    [No Abstract]   [Full Text] [Related]  

  • 7. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Familial hypercholesterolemia].
    Heinzl S
    Med Monatsschr Pharm; 1987 Dec; 10(12):381-7. PubMed ID: 3325786
    [No Abstract]   [Full Text] [Related]  

  • 9. [Heterozygotic familial hypercholesterolemia: argument for early treatment].
    Rosenburg D
    Arch Pediatr; 2004 Nov; 11(11):1410-1. PubMed ID: 15595191
    [No Abstract]   [Full Text] [Related]  

  • 10. Familial hypercholesterolemia: a decade of progress.
    Gidding SS
    J Pediatr; 2010 Feb; 156(2):176-7. PubMed ID: 20105635
    [No Abstract]   [Full Text] [Related]  

  • 11. PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all : Editorial to: "Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/Dl or Higher" by Henry N. Ginsberg et Al.
    Stein EA
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):427-431. PubMed ID: 27669716
    [No Abstract]   [Full Text] [Related]  

  • 12. [Familial hypercholesterolemia].
    Widhalm K
    Dtsch Med Wochenschr; 2000 Jan; 125(4):99. PubMed ID: 10733301
    [No Abstract]   [Full Text] [Related]  

  • 13. Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
    van der Graaf A; Hutten BA; Kastelein JJ; Vissers MN
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):345-51. PubMed ID: 16716095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label).
    Braamskamp MJAM; Langslet G; McCrindle BW; Cassiman D; Francis GA; Gagne C; Gaudet D; Morrison KM; Wiegman A; Turner T; Miller E; Kusters DM; Raichlen JS; Martin PD; Stein EA; Kastelein JJP; Hutten BA
    Circulation; 2017 Jul; 136(4):359-366. PubMed ID: 28592434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Coronary artery bypass graft in adolescent suffering from homozygous familial hypercholesterolemia resistant to probucol therapy].
    Ayegnon KG; Morcos KK; Yangni-Angate KH; Ahmed-Nasr M
    Mali Med; 2009; 24(2):62-4. PubMed ID: 19666374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simvastatin with or without ezetimibe in familial hypercholesterolemia.
    Kaye T
    N Engl J Med; 2008 Jul; 359(5):531-2; author reply 532-3. PubMed ID: 18677800
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia.
    Clauss SB; Holmes KW; Hopkins P; Stein E; Cho M; Tate A; Johnson-Levonas AO; Kwiterovich PO
    Pediatrics; 2005 Sep; 116(3):682-8. PubMed ID: 16140708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia.
    Langslet G; Breazna A; Drogari E
    J Clin Lipidol; 2016; 10(5):1153-1162.e3. PubMed ID: 27678432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
    Mabuchi H; Sakai T; Sakai Y; Yoshimura A; Watanabe A; Wakasugi T; Koizumi J; Takeda R
    N Engl J Med; 1983 Mar; 308(11):609-13. PubMed ID: 6828091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simvastatin with or without ezetimibe in familial hypercholesterolemia.
    Steinberg D
    N Engl J Med; 2008 Jul; 359(5):529; author reply 532. PubMed ID: 18669434
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.